Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported E.P.S. of $8.53 for its fourth fiscal quarter (ending December 31) versus $10.88 for the same period a year ago — a decline of -22%. For the latest four quarters through December 31, E.P.S. were $40.90 compared to $37.05 a year ago — an increase of 10%.
Recent Price Action
On 2/4/25, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock enjoyed a large increase of 4.5%, closing at $697.05. Moreover, this advance was accompanied by unusually high trading volume at 190% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 1.8% during the last week.
Current PriceTarget Research Rating
Regeneron Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Regeneron Pharmaceuticals has a good Appreciation Score of 84 but a poor Power Rating of 24, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment